Consistent with what is observed in renal cell cancer, SYNE1 mutation is associated with an increased TMB in ovarian cancer as well, with 66% of our patients with a SYNE1 mutation having a TMB ≥ 10 [19]. This evidence concerns the gene SYNE1 and renal cell adenocarcinoma.